|
Video: What is a Stock Split?
|
|
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. According to our SUPN split history records, Supernus Pharmaceuticals has had 0 splits. | |
|
Supernus Pharmaceuticals (SUPN) has 0 splits in our SUPN split history database.
Looking at the SUPN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Supernus Pharmaceuticals shares, starting with a $10,000 purchase of SUPN, presented on a split-history-adjusted basis factoring in the complete SUPN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$8.94 |
|
End price/share: |
$33.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
277.40% |
|
Average Annual Total Return: |
14.21% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$37,747.07 |
|
Years: |
10.00 |
|
|
|
|
|